Stocks making the biggest moves midday: Meta, Amylyx, Baidu, Klarna, Coherent, Sandisk & more
Amylyx Pharmaceuticals shares rose 53% after its avexitide treatment met trial endpoints. Meta Platforms fell 3% amid a lawsuit. Carvana dropped 3% after director stock sales. UGI Corporation surged 12% on a $9B KKR bid report. AI-related stocks declined. Klarna fell 21% on weak guidance. Baidu dropped 12% on earnings miss. Home Depot rose slightly on earnings beat. Fabrinet fell 20% on margin concerns. Memory stocks declined. Duolingo rose 7% on an upgrade.
How this was made
The 30-second read
Why it matters
The most tradable items are the explicit Phase 3 endpoint success (Amylyx), guidance/earnings misses (Klarna, Baidu), and the litigation trial kickoff (Meta). Several other declines are framed as correlated risk-off moves rather than new company fundamentals.
Market read
Traders can use the article’s concrete catalysts to update near-term positioning: clinical success and guidance/earnings misses are high-signal, while many AI-linked declines look like sector beta to risk-off.
What to watch
For Meta, the damages figure cited ($1.4T) may be speculative; traders may need to watch procedural milestones and whether the case survives early motions to gauge real tail risk.
Background
This is a CNBC midday market wrap highlighting multiple single-name movers, including a Phase 3 clinical readout, litigation trial kickoff, guidance misses, and sector-wide AI and memory selloffs.
Ticker impact
Meta slid 3% as a group of states sued over alleged harm to children and teens, with damages claimed up to $1.4T.
Choppy downside bias possible while the case develops and investors reprice legal tail risk.
The article highlights a new trial kicked off Tuesday and cites very large potential damages, which can pressure sentiment and risk premia.
Amylyx shares surged 53% after avexitide met its primary and all secondary endpoints in a Phase 3 trial.
Momentum higher likely, with follow-through dependent on confirmatory/regulatory next steps.
A Phase 3 endpoint beat across primary and secondary measures is a concrete, high-impact disclosure tied to the stock move.
Coherent tumbled about 12% as investors took a risk-off posture toward AI buildout-linked photonics stocks.
Likely continued volatility with AI-risk sentiment, but direction may be less idiosyncratic.
The article attributes the drop to broad AI-linked selling, not a new Coherent-specific event.
Lumentum fell about 9% alongside other photonics names as AI buildout-linked stocks sold off.
Near-term downside pressure likely if risk-off persists.
No Lumentum-specific news is provided beyond the correlated selloff.
Ciena lost around 10% during the same AI-linked risk-off move affecting optical networks.
Potential for further weakness if the market continues de-risking AI exposure.
The text provides no Ciena-specific fundamental update, only the sector-linked decline.
Teradyne slid about 9% as AI buildout-linked stocks tanked in Tuesday trading.
Short-term trend likely follows AI-risk appetite rather than company fundamentals.
The article does not cite a Teradyne-specific event, only the correlated sector move.
CoreWeave fell about 9% as AI buildout-linked stocks dropped on a risk-off posture.
Further downside possible if de-risking continues; rebounds possible on sentiment stabilization.
The article states the magnitude of the move and attributes it to AI-linked selling without additional fundamentals.
Klarna tumbled 21% after weak Q3 and full-year guidance versus analyst expectations.
Further downside risk until investors digest revised revenue and GMV outlook.
The article provides specific guidance ranges and compares them to FactSet expectations, indicating a concrete miss.
Market effects
AI buildout-linked photonics, optical networks, and AI infrastructure names sold off together, signaling risk-off rotation within AI supply chain exposure.
US-listed and China-listed names both moved sharply, suggesting broad cross-asset risk repricing rather than a single-region shock.
Memory complex weakness and optical/AI supply chain de-risking point to global demand and capex uncertainty being priced across semis and networking.
Counterpoint
Some declines (Coherent, Lumentum, Ciena, Teradyne, CoreWeave) may be primarily sentiment-driven, so selling could overshoot if no company-specific negatives emerge next.
Key entities
- companyMeta Platforms
Facebook parent facing a states lawsuit trial kickoff with very large claimed damages.
- companyAmylyx Pharmaceuticals
Avexitide Phase 3 trial met primary and all secondary endpoints.
- companyKlarna
Buy-now-pay-later firm cut Q3 and full-year guidance, missing consensus.
- companyBaidu
Q2 results missed EPS and revenue consensus estimates.
- companyHome Depot
Fiscal Q2 beat and reaffirmed full-year guidance.
